Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AUSTIN, TX AND DURHAM, NC, DEC. 15, 2025 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK OR THE COMPANY) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL THERAPEUTICS TARGETING TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTORS FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED THAT IT HAS GRANTED INDUCEMENT EQUITY AWARDS ON DECEMBER 10, 2025 (THE GRANT DATE) TO A NEWLY-HIRED NON-EXECUTIVE OFFICER.

SHATTUCK LABS, INC. ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

AUSTIN, TX AND DURHAM, NC, NOV. 20, 2025 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK OR THE COMPANY) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL THERAPEUTICS TARGETING TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTORS FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN MULTIPLE INVESTOR CONFERENCES IN DECEMBER 2025. CONFERENCE DETAILS CONFERENCE: PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE FORMAT: PRESENTATION AND ONE-ON-ONE MEETINGS PRESENTER: TAYLOR SCHREIBER, M.D.

SHATTUCK LABS TO PARTICIPATE IN UPCOMING DECEMBER INVESTOR CONFERENCES

FIRST PARTICIPANTS DOSED IN PHASE 1 CLINICAL TRIAL OF SL-325 IN HEALTHY VOLUNTEERS   CLOSED A PRIVATE PLACEMENT OF UP TO $103 MILLION IN AUGUST 2025 TO SUPPORT ADVANCEMENT OF SL-325   APPOINTMENTS OF DAN BAKER, M.D., AND MONA ASHIYA, PH.D.

Shattuck Labs, Inc.

STTK

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Shattuck Labs, Inc.

STTK.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

STTK